QIAGEN Gains SFDA Approval to Market careHPV Test in China – Expanding Access to HPV Testing in Low-resource Countries

SHENZEN, China and HILDEN, Germany, November 28, 2012 /PRNewswire/ –

        - Commercial launch of careHPV in China and other emerging markets will
          enable high-quality screening for prevention of cervical cancer
        - "Country of Origin" approval key for dissemination, other countries are able
          to use this as a basis for registration
        - careHPV is the first HPV test designed for areas with limited healthcare
          infrastructure, complementing QIAGEN's market-leading digene HC2 HPV Test

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that China’s
State Food and Drug Administration (SFDA) has approved QIAGEN’s careHPV Test and
instrument platform. The careHPV Test is the first molecular diagnostic to screen for high
risk human papillomavirus (HPV) designed for low-resource clinical settings, such as areas
lacking electricity, water or modern laboratory infrastructure. QIAGEN expects to announce
the product availability of careHPV in China in January 2013, followed by India later in
2013 and other emerging markets as approvals are received. QIAGEN will introduce the
careHPV Test and key data of its performance at the International Papillomavirus (IPV)
conference, starting November 30 in Puerto Rico.

QIAGEN is the global market leader in HPV testing with its “gold standard” digene HC2
HPV Test, the most validated and sensitive diagnostic for detection of high-risk HPV – a
primary cause of cervical cancer. It is the only assay that has demonstrated its
effectiveness in close to 1 million women in clinical, randomized and independent studies.
The digene HC2 test, compatible with modern laboratories and automated processing, is
widely used in developed countries and large cities in emerging markets, including China.
The digene HC2 test has protected more than 100 million women so far and remains QIAGEN’s
core product for cervical cancer prevention. The careHPV and digene HC2 tests are both
based on clinically proven Hybrid Capture technology, and are highly complementary because
they serve different laboratory needs.

QIAGEN developed the careHPV Test in collaboration with PATH, an international
nonprofit organization, to expand access to HPV screening in low-resource settings. The
robust, portable, and easy-to-use careHPV assay, instrument and collection devices are
designed for areas with limited infrastructure and can provide results during the patient
visit. Many regions with the highest burdens of cervical cancer lack electricity, water or
modern laboratory infrastructure. To address the needs in such regions, QIAGEN’s careHPV
Test includes many innovative design and technology features. For example, the system has
color coded, easy to understand menus, contained reagents, and tolerates temperature
variations that occur in rural clinics lacking refrigeration for sample storage due to
limited electricity or water. Non-medical staff can be trained in hours to use the careHPV
system, and the test also has been shown to avoid cross-contamination of samples even in
the most stringent settings.

“As the only test of its kind, careHPV offers the life-saving benefits of sensitive
molecular diagnostics to resource-poor regions. About 275,000 women a year die from
cervical cancer, more than 85 percent in less-developed countries. We have teamed with
PATH to create careHPV as part of a preventive strategy that will save many women’s
lives,” said Dr. Helge Lubenow, Senior Vice President, Molecular Diagnostics Business
Area. “We are expanding QIAGEN’s Prevention portfolio by launching the careHPV system in
emerging markets, both through a commercial offering to healthcare providers and through
donations to governments and NGOs that are in the process of implementing large scale
cervical cancer prevention plans. This new product complements our well-established global
leadership with the digene HC2 HPV test and can also be used very synergistically for
example to allow national or regional screening programs to cover the infrastructure
profiles of all segments within the targeted region.”

The careHPV Test is manufactured by QIAGEN in Shenzhen, China, making the “country of
origin” approval a critical milestone. Many countries are able to use this approval by the
SFDA for their own regulatory approval, instead of conducting lengthy and costly local
regulatory submissions. The careHPV rollout will target areas in Asia, Latin America,
Eastern Europe and Africa.

Clinical studies with the careHPV Test have been conducted in China, Nigeria, Rwanda
and Thailand in parallel with PATH demonstration trials in China, India, Uganda and
Nicaragua. The data demonstrate the high sensitivity and reliability of the careHPV Test
in low-resource settings.

The careHPV Test already plays a central role in QIAGENcares, the company’s
collaboration with NGOs and governments to expand access to high-quality cervical cancer
screening in resource-poor regions. QIAGEN is committed to donating 1.5 million HPV tests
to improve life in the world’s poorest nations. For example, QIAGEN has partnered with
vaccine manufacturer Merck & Co., Inc., to design and implement comprehensive public
programs to fight cervical cancer in poor countries, starting in Rwanda. The programs have
taken many forms: QIAGENcares has helped clinicians in Brazil install the careHPV device
on mobile units to conduct cervical cancer screening in remote areas. El Salvador’s
government, working with the nonprofit group Basic Health International, is evaluating the
integration of careHPV into a national screening program together with screening solutions
based on the digene HC2 test which would be used in cities. Projects in South Africa and
Burkina Faso have also used careHPV. To learn more about QIAGENcares please visit:

http://www.qiagen.com/about/whoweare/qiagencares/qiagencares.aspx.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample &
Assay Technologies that are used to transform biological materials into valuable molecular
information. Sample technologies are used to isolate and process DNA
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
, RNA
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
and proteins from biological samples such as blood or tissue. Assay technologies are
then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN
markets more than 500 products around the world, selling both consumable kits and
automation systems to customers through four customer classes: Molecular Diagnostics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
(human healthcare), Applied Testing
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
(forensics, veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of September 30, 2012,
QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended.
To the extent that any of the statements contained herein relating to QIAGEN’s products,
markets, strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating results and allocations
between customer classes, the commercial development of markets for our products in
applied testing
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
, personalized healthcare, clinical research, proteomics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
, women’s health/HPV
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
testing and nucleic acid
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
-based molecular diagnostics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=388&lang=EN ]
; changing relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products
(including fluctuations due to general economic conditions, the level and timing of
customers’ funding, budgets and other factors); our ability to obtain regulatory approval
of our products; difficulties in successfully adapting QIAGEN’s products to integrated
solutions and producing such products; the ability of QIAGEN to identify and develop new
products and to differentiate and protect our products from competitors’ products; market
acceptance of QIAGEN’s new products, the consummation of acquisitions, and the integration
of acquired technologies and businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities
and Exchange Commission (SEC).

        Contacts:

        Public Relations:
        Dr. Thomas Theuringer
        Director Public Relations
        +49-2103-29-11826
        +1-240-686-7425

        Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/about/press

        Investor Relations:
        John Gilardi
        VP Corporate Communications
        +49-2103-29-11711
        +1-240-686-2222

        Email: ir@qiagen.com

http://www.qiagen.com/about/investorrelation

SOURCE Qiagen N.V.